Synonyms: ent-crizotinib
Compound class:
Synthetic organic
Comment: Inhibition of MTH1 (gene symbol NUDT1) by (S)-crizotinib has revealed small molecule MTH1 inhibitors as a promising new class of anticancer compounds.
|
|
Bioactivity Comments |
(S)-crizotinib has been reported to inhibit the activity of MTH1 (aka NUDT1) with a Kd of 48nM [1]. (R)-crizotinib is an approved anti-cancer drug, targeting ALK, RON and c-Met protein kinases. However, at NUDT1 (R)-crizotinib is less potent (Kd 781nM) than its (S) counterpart [1]. This highlights the necessity that drug compounds be steroespecifically pure when there is a pharmacological difference in activity between stereoisomers (ie they exhibit distinct molecular mechanisms of action), as enantiomerically impure mixtures may result in off-target effects. A number of chemical suppliers and other submitters to online chemistry databases specify the non-stereoisomeric molecule depicted in PubChem CID 11597571. |